AssetMark Inc
JANX icon

AssetMark Inc’s Janux Therapeutics JANX Stock Holding History

AssetMark Inc’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$52 Buy
+3
New +$50 ﹤0.01% 3718

Other funds holding JANX

Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
Congress Asset Management
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
Raiffeisen Bank International
Raiffeisen Bank International Vienna, Austria $8.69B AUM 38.11% 1-Year Est. Return
Tema ETFs
Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return
CenterBook Partners
CenterBook Partners Greenwich, Connecticut $2.18B AUM 12.5% 1-Year Est. Return
Achmea Investment Management
Achmea Investment Management Zeist, Netherlands $12.6B AUM 25.68% 1-Year Est. Return
West Tower Group
West Tower Group Richmond, Virginia $27M AUM 33.41% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return

AssetMark Inc's JANX Position: Q3 2026 in Review

AssetMark Inc opened a new position in Janux Therapeutics (JANX) in Q3 2026: 3 shares worth $52. The stake represents ﹤0.01% of the portfolio and ranks #3718 among its holdings.

44 funds tracked by Wall St. Rank hold JANX as of Q3 2026.

  • AssetMark Inc held 3 shares of Janux Therapeutics worth $52 as of Q3 2026.
  • Janux Therapeutics was a new AssetMark Inc position in Q3 2026.
  • Janux Therapeutics made up ﹤0.01% of AssetMark Inc's portfolio in Q3 2026, its #3718 holding.
  • 44 funds tracked by Wall St. Rank held Janux Therapeutics as of Q3 2026.

Based on AssetMark Inc's 13F filing for Q3 2026, filed 21 Oct 2026.